A- A A+

Both localized and systemic bacterial infections are predicted by injection drug use: A prospective follow-up study in Swedish criminal justice clients.

Dahlman D, Berge J, Björkman P, Nilsson AC, Håkansson A (2018) 

PLoS ONE 13(5): e0196944. doi.org/10.1371/journal.pone.0196944


EMCDDA. New psychoactive substances in prison 

Rapid Communication, Publications Office of the European Union, Luxembourg, 2018


Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study

Cunningham, Evan B. et al.

International Journal of Drug Policy , Volume 54 , 18 - 25


EMCDDA. New psychoactive substances in prison (Video)

The use of new psychoactive substances (NPS) among prisoners appears to be a rapidly developing phenomenon. But empirical data are currently scarce and patchy. A recent study suggests that synthetic cannabinoids are the most common group of NPS used in prison. (EMCDDA, Lissabon, 07.06.2018, Video, 01:37)


Methadone Versus Torture: The Perspective of the European Court of Human Rights

Junod V., Wolff H., Scholten W., Novet B., Greifinger R., Dickson C., and Simon O.

Heroin Addiction and Related Clinical Problems 20(1):31-36 · February 2018


Initiating buprenorphine treatment prior to versus after release from prison: Arrest outcomes.

Gordon MS, Blue TR, Couvillion K, Schwartz RP, O'Grady KE, Fitzgerald TT, Vocci FJ.

Drug Alcohol Depend. 2018 May 12;188:232-238. doi: 10.1016/j.drugalcdep.2018.04.010. 



Systematic review of qualitative evaluations of reentry programs addressing problematic drug use and mental health disorders amongst people transitioning from prison to communities

Sacha Kendall, Sarah Redshaw, Stephen Ward, Sarah Wayland and Elizabeth Sullivan

Health & Justice2018, 6:4, doi.org/10.1186/s40352-018-0063-8


EMCDDA. Public health guidance on active case finding of communicable diseases in prison settings


What are the most (cost-) effective ways to prevent and control communicable diseases in prison settings? In their joint public health Guidance, ECDC and the EMCDDA, present the evidence on active case finding as a key measure to diagnose communicable diseases early. The two agencies advise to actively offer testing for hepatitis B, hepatitis C and HIV to all people in prison and to conduct universal testing for tuberculosis at prison entry. (EMCDDA,ECDC,Lissabon,Mai 2018)


Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey.

Kouyoumdjian FG, Patel A, To MJ, Kiefer L, Regenstreif L (2018)

PLoS ONE 13(2): e0192431. https://doi.org/10.1371/journal.pone.0192431



HCV: Elimination von Hepatitis C Infektionen in Gefängnissen – Ziele vs. Realität

Stöver, H. und Keppler, K.

Praxis Report, Heft 5, 10.Jahrgang, Mai 2018


Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review.

Kinner SA, Snow K, Wirtz AL, Altice FL, Beyrer C, Dolan K.

J Adolesc Health. 2018 Mar;62(3S):S18-S26. doi: 10.1016/j.jadohealth.2017.09.030.


Global Prison Trends 2018

(Penal Reform International and Thailand Institute of Justice Global Prison Trends 2018) 


Substitutionsbehandlung im Strafvollzug - Ein praktischer Leitfaden

Jörg Pont, Andrej Kastelic, Heino Stöver, Catherine Ritter, Bärbel Knorr

DAH – Deutsche AIDS-Hilfe, 2018


Kanada. Canada to test first needle exchange program in a North American prison 

Program aims to stop the spread of infections such as HIV, Aids and hepatitis C among inmates who are drug users. (The Guardian, UK, 15.05.2018)


A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release.

Brinkley-Rubinstein L, McKenzie M, Macmadu A, Larney S, Zaller N, Dauria E, Rich J.

Drug Alcohol Depend. 2018 Mar 1;184:57-63. doi: 10.1016/j.drugalcdep.2017.11.023.



Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries

Rob Bielen,Samya R. Stumo,Rachel Halford,Klára Werling,Tatjana Reic,Heino Stöver,Geert Robaeys†and Jeffrey V. Lazarus†(Contributed equall)y

Harm Reduction Journal 2018 15:25, doi.org/10.1186/s12954-018-0230-1


Why It's Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy.

Wakeman SE.

AMA J Ethics. 2017 Sep 1;19(9):922-930. doi: 10.1001/journalofethics.2017.19.9.stas1-1709.


Health Outcomes for Clients of Needle and Syringe Programs in Prisons.

Lazarus JV, Safreed-Harmon K, Hetherington KL, Bromberg DJ, Ocampo D, Graf N, Dichtl A, Stöver H, Wolff H.

Epidemiol Rev. 2018 Apr 12. doi: 10.1093/epirev/mxx019.



Substitution in Haft - Deine Rechte, Deine Möglichkeiten

In vielen Justizvollzugsanstalten wird nicht bzw. wird nicht ausreichend substituiert. Die Broschüre bietet Informationen für Substituierte, die von Inhaftierung bedroht sind und zeigt Gefangenen, die sich vergeblich um eine Substitution bemühen, welche rechtlichen Schritte möglich sind. (DAH, 2018)


Prevalence of hepatitis C virus infection among prisoners in Iran: a systematic review and meta-analysis

Masoud Behzadifar,Hasan Abolghasem Gorji, Aziz Rezapourand Nicola Luigi Bragazzi

Harm Reduction Journal 2018 15:24, doi.org/10.1186/s12954-018-0231-0


USA. Moving Ahead on Methadone in Corrections

People who get incarcerated—in prisons or jails—tend to be people with more advanced addiction. If they have opioid use disorders, they typically spend their term without any opioids. When they are released, their tolerance has decreased, and if they relapse—which is likely—they may overdose. That danger was never as great as it is now, explained Josiah D. Rich, MD, MPH, professor of Medicine and Epidemiology at The Warren Alpert Medical School of Brown University, and director of the Center for Prisoner Health and Human Rights at The Miriam Hospital in Providence, Rhode Island.

“The stakes have gotten a lot higher,” Dr. Rich told AT Forum. “We send them back out into the community when the illicit opioid supply has never been so lethal.”

Rhode Island, under the leadership of Gov. Gina Raimondo, has led the state’s initiative to expand opioid treatment with medications to the prison and jail system. She put over $1 million a year into her budget that the General Assembly approved to screen incarcerated people for opioid use disorder and offer them medications for addiction treatment (MAT). Dr. Rich, who treats incarcerated patients, works as a consultant to the Department of Corrections, alongside CODAC Behavioral Healthcare, a not-for-profit opioid treatment program (OTP) that delivers methadone and buprenorphine to inmates. (ATForum, 12.02.2018)


HIV and Viral Hepatitis Among Imprisoned Key Populations.

Wirtz AL, Yeh PT, Flath NL, Beyrer C, Dolan K.

Epidemiol Rev. 2018 Apr 21. doi: 10.1093/epirev/mxy003.



USA. Methadone improves inmate outcomes

Jail inmates who continue to receive methadone treatment for opioid use disorder have better outcomes both during and after incarceration, according to a new Yale study conducted in conjunction with several state agencies. (Yale News, 02.02.2018)


Dual diagnosis of mental illness and substance use disorder and injury in adults recently released from prison: a prospective cohort study

Young, Jesse T et al.

The Lancet Public Health , Volume 0 , Issue 0 , Published: 18 April 2018 , doi.org/10.1016/S2468-2667(18)30052-5


Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System.

Traci C. Green, Jennifer Clarke, Lauren Brinkley-Rubinstein, Brandon D. L. Marshall, Nicole Alexander-Scott, Rebecca Boss, Josiah D. Rich.

JAMA Psychiatry, 2018; DOI: 10.1001/jamapsychiatry.2017.4614

Research letter, first page


Conclusions of the WHO international meeting on prisons and health, Lisbon 2017

Drugs and drug-related harms continue to challenge prison systems in Europe and interventions in this setting must be driven by evidence gathered through monitoring, data-collection and research. The remarks come in conclusions published by the World Health Organization Regional Office for Europe (WHO–Europe), in collaboration with Public Health England and the EMCDDA. (EMCDDA, Lissabon, 13.04.2018)